NBIX - ニュ―ロクライン・バイオサイエンシズ (Neurocrine Biosciences Inc.) ニュ―ロクライン・バイオサイエンシズ

 NBIXのチャート


 NBIXの企業情報

symbol NBIx
会社名 Neurocrine Biosciences Inc. (ニュ―ロクライン・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ニューロクライン・バイオサイエンシス(Neurocrine Biosciences Inc)は神経と内分泌関連疾患及び障害の治療薬の発見・開発・商業化に従事する企業。同社の薬品候補は子宮内膜症、ストレス関連疾患、疼痛、糖尿病、不眠症、及び他の神経と内分泌関連疾患及び障害などの製薬市場に提供する。同社は各自の研究・開発段階にある11のプログラムを持ち、そのうち、6つのプログラムは臨床開発段階にある。同社は6つのプログラムのためのコラボレーションを締結した。同社の主要な臨床開発プログラム「elagolix」は子宮内膜症治療用の薬剤候補。同社の製品ポートフォリオは「Elagolix」、小胞モノアミントランスポーター2阻害剤(VMAT2)、コルチコトロピン遊離因子タイプ2(CRF2)ペプチド・アゴニストウロコルチン、コルチコトロピン遊離因子タイプ1(CRF1)拮抗薬(561679)、コルチコトロピン遊離因子タイプ1(CRF1)拮抗薬(586529)、Gタンパク質共役型受容体119(GPR119)、VMAT2、性腺刺激ホルモン放出ホルモン(GnRH)拮抗薬、抗てんかん薬、Gタンパク質共役受容体と「Indiplon」などを含む。   ニュ―ロクライン・バイオサイエンシズは米国のバイオ医薬品メ―カ―。主に、神経及び内分泌関連疾患や障害である、子宮内膜症、糖尿病、睡眠障害、疼痛、ストレス性障害、てんかんなどの治療薬の臨床・開発に従事する。カリフォルニア州サンディエゴに拠点を置き、世界的に事業を展開。   
本社所在地 12780 El Camino Real San Diego CA 92130 USA
代表者氏名 William H. Rastetter ウィリアムH.ラスターセッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-617-7600
設立年月日 33604
市場名 NASDAQ National Market System
ipoyear 1996年
従業員数 400人
url www.neurocrine.com
nasdaq_url https://www.nasdaq.com/symbol/nbix
adr_tso
EBITDA EBITDA(百万ドル) -30.46900
終値(lastsale) 112.3
時価総額(marketcap) 10159709240.3
時価総額 時価総額(百万ドル) 9776.119
売上高 売上高(百万ドル) 323.28200
企業価値(EV) 企業価値(EV)(百万ドル) 9646.264
当期純利益 当期純利益(百万ドル) -51.96200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Neurocrine Biosciences Inc. revenues increased from $6.3M to $168M. Net loss decreased 65% to $47.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investment income net increase from $1.9M to $6.3M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.58 to -$0.53.

 NBIXのテクニカル分析


 NBIXのニュース

   Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)  2021/03/02 12:30:00 PR Newswire
SAN DIEGO, March 2, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by…
   Malcolm Lloyd-Smith Sells 865 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock  2021/02/11 12:00:41 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Malcolm Lloyd-Smith sold 865 shares of the firm’s stock in a transaction on Friday, February 5th. The stock was sold at an average price of $114.15, for a total value of $98,739.75. Following the sale, the insider now owns 29,675 shares in the company, valued at approximately $3,387,401.25. The transaction […]
   Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $275,951.14 in Stock  2021/02/10 02:56:57 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eiry Roberts sold 2,363 shares of the firm’s stock in a transaction on Monday, February 8th. The shares were sold at an average price of $116.78, for a total value of $275,951.14. Following the completion of the transaction, the insider now owns 17,231 shares of the company’s stock, valued at […]
   Neurocrine exits $165M Parkinson's pact with Voyager after FDA hold  2021/02/03 15:01:09 FierceBiotech
In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics. Now, it’s pulling out of the Parkinson’s disease portion of the deal, thanks to safety issues that have led to an FDA clinical hold.
   Neurocrine axes Parkinson's collab with Voyager after safety issues, jeopardizing biotech's long-running centerpiece  2021/02/02 22:07:11 Endpoints News
Six years ago, Third Rock Ventures launched Voyager Therapeutics with $45 million and a goal of bringing gene therapy into some of the most notorious neurological diseases, most notably Parkinson's. Now that program, long their lead and only clinical asset, is in jeopardy. Voyager announced Tuesday afternoon that Neurocrine Biosciences
   Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)  2021/03/02 12:30:00 PR Newswire
SAN DIEGO, March 2, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by…
   Malcolm Lloyd-Smith Sells 865 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock  2021/02/11 12:00:41 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Malcolm Lloyd-Smith sold 865 shares of the firm’s stock in a transaction on Friday, February 5th. The stock was sold at an average price of $114.15, for a total value of $98,739.75. Following the sale, the insider now owns 29,675 shares in the company, valued at approximately $3,387,401.25. The transaction […]
   Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $275,951.14 in Stock  2021/02/10 02:56:57 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eiry Roberts sold 2,363 shares of the firm’s stock in a transaction on Monday, February 8th. The shares were sold at an average price of $116.78, for a total value of $275,951.14. Following the completion of the transaction, the insider now owns 17,231 shares of the company’s stock, valued at […]
   Neurocrine exits $165M Parkinson's pact with Voyager after FDA hold  2021/02/03 15:01:09 FierceBiotech
In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics. Now, it’s pulling out of the Parkinson’s disease portion of the deal, thanks to safety issues that have led to an FDA clinical hold.
   Neurocrine axes Parkinson's collab with Voyager after safety issues, jeopardizing biotech's long-running centerpiece  2021/02/02 22:07:11 Endpoints News
Six years ago, Third Rock Ventures launched Voyager Therapeutics with $45 million and a goal of bringing gene therapy into some of the most notorious neurological diseases, most notably Parkinson's. Now that program, long their lead and only clinical asset, is in jeopardy. Voyager announced Tuesday afternoon that Neurocrine Biosciences
   Neurocrine exits $165M Parkinson's pact with Voyager after FDA hold  2021/02/03 15:01:09 FierceBiotech
In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics. Now, it’s pulling out of the Parkinson’s disease portion of the deal, thanks to safety issues that have led to an FDA clinical hold.
   Neurocrine axes Parkinson's collab with Voyager after safety issues, jeopardizing biotech's long-running centerpiece  2021/02/02 22:07:11 Endpoints News
Six years ago, Third Rock Ventures launched Voyager Therapeutics with $45 million and a goal of bringing gene therapy into some of the most notorious neurological diseases, most notably Parkinson's. Now that program, long their lead and only clinical asset, is in jeopardy. Voyager announced Tuesday afternoon that Neurocrine Biosciences
   Kevin Charles Gorman Sells 308,250 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock  2021/01/14 09:22:59 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 308,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $110.22, for a total value of $33,975,315.00. Following the completion of the sale, the chief executive officer now owns 584,520 shares in […]
   Neurocrine Biosciences Announces Repurchase of Convertible Notes  2020/11/19 13:00:00 PR Newswire
SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024…
   Neurocrine Biosciences Reports Third Quarter 2020 Financial Results  2020/11/09 21:01:00 Benzinga
SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance. "Our focus remains on helping as many patients with tardive dyskinesia as possible and we are adapting to the challenges posed by the pandemic, including the slow recovery of in-person visits with psychiatrists. We are encouraged by recent trends and remain confident in the intermediate and long-term opportunity of INGREZZA to help many more patients with tardive dyskinesia," said Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We are pleased to expand our reach with neurologists with the addition of ONGENTYS to our movement disorder portfolio and continue to advance our development programs focused on neurological, endocrine and psychiatric disorders." Financial Highlights Three Months Ended September 30, Nine Months Ended September 30, (unaudited, in millions, except per share data) 2020 2019 2020 2019 Revenues: Product sales, net $ 254.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ニュ―ロクライン・バイオサイエンシズ NBIX Neurocrine Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)